Development of a Novel Tropomyosin Receptor Kinase Inhibitor Based on Structure–Activity Relationships: Identification of a Promising Clinical Candidate

Abstract

Tropomyosin receptor kinase (TRK) inhibitors have emerged as promising therapeutic agents for various cancers. In this study, we report the discovery and characterization of CH7070868, a novel and potent TRK-selective inhibitor. Through structure–activity relationship studies, we optimized the lead compound (CH7057288) to achieve superior TRK inhibition while reducing the risk of drug–drug interactions (CYP3A4 induction). CH7070868 demonstrated high selectivity for TRK over other kinases (KDR and LCK) and exhibited potent inhibitory activity in both biochemical and cellular assays. Our findings suggest that CH7070868 represents a promising candidate for further development as a next-generation TRK inhibitor with an enhanced efficacy.

Key words

TRK inhibitor - structure–activity relationship - CH7070868 - NTRK fusion gene - antiproliferative activity - CYP3A4 induction - selectivity - hydroxy group

• References and Notes

• 1 Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC. Nat. Med. 2013; 19: 1469
• 2 Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. Nat. Commun. 2014; 5: 4846
• 3a Jones DT. W, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz H.-J, Zichner T, Lambert SR, Ryzhova M, Quang DA. K, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann M, Cho Y.-J, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo M.-L, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM. Nat. Genet. 2013; 45: 927
• 3b Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH. B. Cancer Cell 2002; 2: 367
• 4a Bailey JJ, Jaworski C, Tung D, Wängler C, Wängler B, Schirrmacher R. Expert Opin. Ther. Pat. 2020; 30: 325
• 4b Yan E, Rajiv Lakkaniga N, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li H.-Y. J. Med. Chem. 2019; 62: 1731
• 4c Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Lombardi Borgia A, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P. J. Med. Chem. 2016; 59: 3392
• 5 Laetsch TW, Hong DS. Clinical Cancer Research 2021; 27: 4974
• 6 Ito T, Kinoshita K, Tomizawa M, Shinohara S, Nishii H, Matsushita M, Hattori K, Kohchi Y, Kohchi M, Hayase T, Watanabe F, Hasegawa K, Tanaka H, Kuramoto S, Takanashi K, Oikawa N. J. Med. Chem. 2022; 65: 12427
• 7 FDA guidance for industry, in vitro drug interaction studies – cytochrome P450 enzyme- and transporter-mediated drug interactions (accessed January 6, 2025): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies
• 8 Guideline on the investigation of drug interactions. European Medicines Agency; London: 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
• 9 Kuramoto S, Kato M, Shindoh H, Kaneko A, Ishigai M, Miyauchi S. Drug Metab. Dispos. 2017; 45: 1139